<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2063">
  <stage>Registered</stage>
  <submitdate>29/07/2008</submitdate>
  <approvaldate>29/07/2008</approvaldate>
  <nctid>NCT00725036</nctid>
  <trial_identification>
    <studytitle>Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes</studytitle>
    <scientifictitle>A 24-month Multicentre, Open-label, Randomised, Parallel Group, Long Term Safety Trial Comparing Intensive Treatment of Pulmonary Inhaled Human Insulin With Insulin Aspart Administered s.c., Both in Combination With NPH, in Subjects With Type 1 Diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NN1998-1496</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <healthcondition>Diabetes Mellitus, Type 1</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - inhaled human insulin
Treatment: drugs - insulin aspart
Treatment: drugs - insulin NPH

Treatment: drugs: inhaled human insulin


Treatment: drugs: insulin aspart


Treatment: drugs: insulin NPH


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Long term pulmonary safety profiles</outcome>
      <timepoint>during treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Glycaemic control as measured by HbA1c</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of hypoglycaemic episodes</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Long-term safety profiles (laboratory, ECG, insulin antibodies)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physical examination and body weight and vital signs</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment satisfaction</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 1 diabetes

          -  Current treatment with any insulin in any regimen

          -  Body mass index (BMI) below 38.0 kg/m2

          -  HbA1c below or equal to 13.0%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Total daily insulin dosage more than 100 IU/day

          -  Current acute or chronic pulmonary disease (excluding asthma)

          -  Recurrent major hypoglycaemia

          -  Proliferative retinopathy or maculopathy requiring acute treatment

          -  Smoker

          -  Chest X-ray with clinically significant abnormalities</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>2/09/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>305</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>14/12/2004</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA</recruitmentstate>
    <hospital>Novo Nordisk Investigational Site - Broadmeadow</hospital>
    <hospital>Novo Nordisk Investigational Site - Camperdown</hospital>
    <hospital>Novo Nordisk Investigational Site - St Leonards</hospital>
    <hospital>Novo Nordisk Investigational Site - Wollongong</hospital>
    <hospital>Novo Nordisk Investigational Site - Woolloongabba</hospital>
    <hospital>Novo Nordisk Investigational Site - Keswick</hospital>
    <hospital>Novo Nordisk Investigational Site - Fremantle</hospital>
    <hospital>Novo Nordisk Investigational Site - Ashford</hospital>
    <hospital>Novo Nordisk Investigational Site - Auckland</hospital>
    <hospital>Novo Nordisk Investigational Site - Box Hill</hospital>
    <hospital>Novo Nordisk Investigational Site - Christchurch</hospital>
    <hospital>Novo Nordisk Investigational Site - Clayton</hospital>
    <hospital>Novo Nordisk Investigational Site - Garran</hospital>
    <hospital>Novo Nordisk Investigational Site - Heidelberg</hospital>
    <hospital>Novo Nordisk Investigational Site - Parkville</hospital>
    <hospital>Novo Nordisk Investigational Site - Perth</hospital>
    <hospital>Novo Nordisk Investigational Site - Randwick</hospital>
    <hospital>Novo Nordisk Investigational Site - Stones Corner</hospital>
    <postcode>2292 - Broadmeadow</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2500 - Wollongong</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5035 - Keswick</postcode>
    <postcode>6160 - Fremantle</postcode>
    <postcode>5035 - Ashford</postcode>
    <postcode> - Auckland</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode> - Christchurch</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>2605 - Garran</postcode>
    <postcode>3085 - Heidelberg</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6000 - Perth</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>4120 - Stones Corner</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novo Nordisk A/S</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is conducted in Oceania.

      The aim of this trial is to compare the safety of using pulmonary inhaled human insulin to
      s.c. insulin aspart both combined with NPH insulin in subjects with type 1 diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00725036</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Registry (GCR, 1452)</name>
      <address>Novo Nordisk A/S</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>